Description
Pandion Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address the unmet needs of patients suffering from autoimmune diseases. The firm has combined a network-based conceptualization of the immune system in advanced protein engineering to develop TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform. Its pipeline products are PT101, for the treatment of patients with moderate-to-severe ulcerative colitis and the treatment of patients with systemic lupus erythematosus; PT627; PT001; and others.
